Besides, selective anaplastic lymphoma kinase (ALK) inhibitors is a first-line therapy for nucleophosmin (NPM)-ALK-positive T cell lymphoma and echinoderm microtubule-associated protein like 4 (EML4)-ALK-positive non-small cell lung cancer (NSCLC) [133, 134]. This evidence concerns the gene NPM1 and non-small cell lung carcinoma.